

GPDPLQ₁₂₃₇—A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation *in vitro*


Henrik Löfvall^{1,2}, Anna Katri^{1,3}, Aneta Dąbrowska¹, Morten A. Karsdal¹, Yunyun Luo¹, Yi He¹,
Tina Manon-Jensen¹, Morten H. Dziegiel⁴, Anne-Christine Bay-Jensen¹, Christian S. Thudium¹,
Kim Henriksen¹

¹Nordic Bioscience, Herlev, Denmark.

²Division of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund, Sweden.

³Department of Drug Design and Pharmacology, Copenhagen University, Copenhagen, Denmark.

⁴Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.



Supplementary Figure S1. GPDPLQ₁₂₃₇ release into BEX supernatants upon stimulation and inhibition of MMP activity. The BEX cultures were untreated (w/o), treated with OSM and TNF α (OT) without protease inhibitors, or OT with the protease inhibitors GM6001 (OT + GM6001) or E-64 (OT + E-64). Data from one representative experiment are presented as the mean GPDPLQ₁₂₃₇ levels per group at different time points throughout the experiment (a) and as the AUCs of each individual explant (b). Error bars represent the SEMs. Statistical significance levels relative to the OT condition in the AUC data are indicated by * $P < 0.05$.